Suscribirse

Incremental Weight Loss Improves Cardiometabolic Risk in Extremely Obese Adults - 29/09/11

Doi : 10.1016/j.amjmed.2011.04.033 
William D. Johnson, PhD , Meghan M. Brashear, MPH, Alok K. Gupta, MD, Jennifer C. Rood, PhD, Donna H. Ryan, MD
Pennington Biomedical Research Center, Baton Rouge, La 

Requests for reprints should be addressed to William D. Johnson, PhD, Pennington Biomedical Research Center, 6400 Perkins Road, Baton Rouge, LA 70808-4124

Abstract

Objective

Excessively obese adults often acquire many metabolic disorders that put them at high risk for developing type 2 diabetes mellitus and cardiovascular disease. We investigated the hypothesis that cardiometabolic risk in a primary care cohort of 208 excessively obese adults (body mass index 40-60 kg/m2, 48 with type 2 diabetes mellitus) would deteriorate with additional weight gain and improve incrementally beginning with 5% weight reduction.

Methods

Further analysis of the Louisiana Obese Subjects Study of excessively obese patients enrolled and followed during 2005-2008 is reported.

Results

Weight loss correlated significantly with improvements in fasting plasma glucose, triglycerides, high- and low-density lipoprotein cholesterol, uric acid, alanine aminotransferase, lactate dehydrogenase, and high-sensitivity C-reactive protein. Most parameters deteriorated with weight gain and progressively improved with 5% or more weight loss. Except for low-density lipoprotein cholesterol, all risk factors significantly improved with20% loss of body weight. Among patients who had not been diagnosed with type 2 diabetes mellitus and had normoglycemia at baseline, median fasting plasma glucose increased significantly (13%) with stable or gained weight at 1 year, but did not change significantly with reduced weight. Although glucose levels did not change significantly in patients with type 2 diabetes mellitus who gained weight, a decline beginning after 5% weight reduction culminated in 25% glucose reduction with20% weight loss. Resting blood pressure declined independently of weight change.

Conclusion

Very obese adults can improve their cardiometabolic risk under primary care weight management. Incremental success may help motivate further therapeutic weight reduction.

El texto completo de este artículo está disponible en PDF.

Keywords : Cardiometabolic benefits of weight reduction, Diabetes, Pragmatic weight loss for class III obesity


Esquema


 Funding: The Louisiana Obese Subjects Study was funded by the Office of Group Benefits, the health insurance provider for Louisiana state employees. Some of the sibutramine used in the Louisiana Obese Subjects Study was donated by Abbott Laboratories (Columbus, OH).
 Conflict of Interest: None of the authors have any conflicts of interest associated with the work presented in this manuscript.
 Authorship: All authors had access to the data and played a role in writing this manuscript.
 Trial registration: ClinicalTrials.gov NCT00115063.


© 2011  Elsevier Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 124 - N° 10

P. 931-938 - octobre 2011 Regresar al número
Artículo precedente Artículo precedente
  • The Obesity Paradox and Weight Loss
  • Jonathan Myers, Kusum Lata, Shilpy Chowdhury, Paul McAuley, Nikhil Jain, Victor Froelicher
| Artículo siguiente Artículo siguiente
  • Long-term Trends in Short-term Outcomes in Acute Myocardial Infarction
  • Hoa L. Nguyen, Jane S. Saczynski, Joel M. Gore, Molly E. Waring, Darleen Lessard, Jorge Yarzebski, George Reed, Frederick A. Spencer, Shu-xia Li, Robert J. Goldberg

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.